Rubric Capital Management (New York)’s Karyopharm Therapeutics KPTI Stock Holding History

Rubric Capital Management (New York)’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-61,280	Closed	-$1.65M	–	65
2023 Q2	$1.65M	Sell	61,280 -234,790	-79%	-$10.1M	0.07%	60
2023 Q1	$17.3M	Sell	296,070 -256,905	-46%	-$12.7M	0.45%	47
2022 Q4	$28.2M	Buy	552,975 +286,967	+108%	+$19.9M	1.23%	27
2022 Q3	$21.8M	Sell	266,008 -27,325	-9%	-$2.04M	1.1%	32
2022 Q2	$19.8M	Buy	293,333 +52,837	+22%	+$4.85M	1.04%	31
2022 Q1	$26.6M	Buy	240,496 +55,000	+30%	+$6.86M	0.96%	28
2021 Q4	$17.9M	Sell	185,496 -39,555	-18%	-$3.94M	0.85%	37
2021 Q3	$19.6M	Sell	225,051 -58,496	-21%	-$6.07M	0.55%	38
2021 Q2	$43.9M	Buy	+283,547	New	+$41.2M	2.76%	16

Other funds holding KPTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rubric Capital Management (New York)'s KPTI Position: Q3 2023 in Review

Rubric Capital Management (New York) sold out of Karyopharm Therapeutics (KPTI) in Q3 2023, closing a stake of 61,280 shares — an estimated $1.65M sold.

Rubric Capital Management (New York) first reported a position in KPTI in Q2 2021 and held it in 9 quarters. The position peaked at $43.9M in Q2 2021. 118 funds tracked by Wall St. Rank hold KPTI as of Q3 2023.

Rubric Capital Management (New York) reported no remaining Karyopharm Therapeutics position as of Q3 2023 after selling out during the quarter.
Rubric Capital Management (New York) sold 61,280 Karyopharm Therapeutics shares in Q3 2023, an estimated $1.65M.
Rubric Capital Management (New York) first reported a position in Karyopharm Therapeutics in Q2 2021 and held it in 9 quarters.
Rubric Capital Management (New York)'s Karyopharm Therapeutics position peaked at $43.9M in Q2 2021.
118 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2023.

Based on Rubric Capital Management (New York)'s 13F filing for Q3 2023, filed 14 Nov 2023.